You are here
- Home
- Therapy Areas
- Respiratory/Inflammation
A randomised, parallel-group, open-label, multicentre, 3-month phase IV, efficacy and tolerability study of budesonide/formoterol (Symbicort® Turbuhaler® 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (SpirivaTM 18 μg/inhalation, 1 inhalation once daily) compared with tiotropium (SpirivaTM18 μg/inhalation, 1 inhalation once daily) alone in severe chronic obstructive pulmonary disease (COPD) patients
- Disease
- asthma
- Drug Name
- Symbicort Turbuhaler
- Generic Name
- budesonide/formoterol
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IV
- Start Date
- Jan 18, 1971
- Study Name
- SECURE 1
- Study Id
- D589BL00023
- ClinicalTrials.gov ID
- NCT01397890
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
